Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small. Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you’re going to be tak
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.